The FDA officially approved Ocrelizumab (brand name: Ocrevus) for use in multiple sclerosis treatment on March 28, 2017. In this live Q&A, Dr. Timothy Vollmer answers some common questions on this new option for MS patients.
PRESENTER:
Dr. Timothy Vollmer is a graduate of Stanford University School of Medicine and a former faculty member at the Yale School of Medicine. Retiring at the end of 2021, he has served as Director of Neurology Clinical Research at the University of Colorado Anschutz campus, the Medical Director of the RMMSC and Co-Director of the Rocky Mountain Multiple Sclerosis Center at University of Colorado.